CCNE2 and ovarian cancer: As a cell cycle progressor, CCNE2 has been shown to promote proliferation of cancer cells, as demonstrated, e.g. in prostate or ovarian cancer (Xie et al., 2017; Liu et al., 2020; Fagundes and Teixeira, 2021).